MedTrace Logo

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

NCT05314296 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-04-06

No results posted yet for this study

Summary

The purpose of this study is to assess safety of Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after therapy with a prior EGFR tyrosine kinase inhibitor (TKI), with confirmed Т790М positive mutation in EGFR gene.

Conditions

  • Non Small Cell Lung Cancer
  • T790M
  • EGFR Gene Mutation

Sponsors & Collaborators

  • N.N. Blokhin National Medical Research Center of Oncology

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05314296 on ClinicalTrials.gov